EX-FILING FEES 6 d335310dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Form S-1

CinCor Pharma, Inc.

Table 1 – Newly Registered Securities

 

                 
     Security
Type
 

Security

Class

Title

  Fee
  Calculation  
Rule
  Amount
  Registered  
  Proposed
  Maximum  
Offering
Price Per
Unit
  Maximum
  Aggregate  
Offering
Price(1)(2)
 

Fee

Rate

  Amount of
 Registration 
Fee
                 

Fees to be

Paid

    Equity     Common stock,
 $0.00001 par value per 
share(3)(4)
  457(o)   —     —     $247,365,000   .0000927    $22,931
                 

Fees to be

Paid

  Equity   Pre-funded warrants
to purchase common stock(4)
  Other   —     —     —     —     —  
                 

Fees to be

Paid

  Equity   Common stock issuable upon
exercise of pre-funded
warrants(4)
  457(o)   —     —     —     —     —  
                 

Fees

Previously

Paid

  —     —     —     —     —     —     —     —  
           
    Total Offering Amounts    —     $247,365,000   —     $22,931
           
    Total Fees Previously Paid    —     —     —     —  
           
    Total Fee Offsets    —     —     —     —  
           
    Net Fee Due    —     —     —     $22,931

 

(1)

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended, or the Securities Act.

(2)

Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover an indeterminate number of additional securities that may from time to time be offered or issued to prevent dilution as a result of share splits, share dividends, dividends or other distributions, reclassifications, or similar transactions.

(3)

Includes shares of common stock that the underwriters have the option to purchase.

(4)

The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $247,365,000 (including the underwriters’ option to purchase additional shares of common stock).